Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amlodipine Maleate

FDA-approved product (tablet, oral), marketed as Amlodipine Benzoate, Katerzia, Amlodipine Besylate and 4 more.

Registered studies
2
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Amlodipine Maleate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angina pectoris
  • Cardiovascular disease
  • Congestive heart failure
  • Coronary artery disease
  • Diabetes mellitus
  • Familial hypercholesterolemia
  • Heart failure
  • Hypercholesterolemia
  • Hyperlipidemia
  • Hypertension
  • Myocardial infarction
  • Osteoarthritis
  • Prinzmetal's angina
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dihydropyridine derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

2registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Amlodipine Maleate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-4.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amlodipine Maleate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

    NCT04467931 · start 2020-01-19

    Registered record
    Registry ID
    NCT04467931
    Conditions
    Hypertension; COVID
    Interventions
    ACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-01-19
    Completion
    2020-12-31
    Enrolment
    22,213

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; COVID
    InterventionACEI/ARB; Non-ACEI/ARB; ACEI; ARB
    PhaseNot recorded
    Registry statusCompleted

  • Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients

    NCT02474420 · start 2015-06

    Registered record
    Registry ID
    NCT02474420
    Conditions
    Beta-Thalassemia; Iron Overload
    Interventions
    Amlodipine; Deferasirox
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2015-06
    Completion
    2018-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBeta-Thalassemia; Iron Overload
    InterventionAmlodipine; Deferasirox
    PhaseNot applicable
    Registry statusUnknown